Literature DB >> 15050449

Clinical correlates of serum anti-GT1a IgG antibodies.

Takahide Nagashima1, Michiaki Koga, Masaaki Odaka, Koichi Hirata, Nobuhiro Yuki.   

Abstract

Patients with the pharyngeal-cervical-brachial variant (PCB) of Guillain-Barré syndrome (GBS) have anti-GT1a IgG with or without GQ1b reactivity, whereas those with Fisher syndrome (FS) or Bickerstaff's brainstem encephalitis (BBE) have anti-GQ1b IgG antibodies which cross-react with GT1a. The nosological relationship between these conditions has yet to be established. To investigate the relationships between each manifestation and between clinical features and the coexistence of anti-GQ1b IgG, we reviewed neurological signs present during illnesses of 140 patients who had anti-GT1a IgG. Based on our criteria, FS was diagnosed for 64 (46%) patients, GBS for 22 (16%), BBE for 14 (10%), and PCB for 6 (4%). Overlapping conditions were diagnosed for some patients: FS and GBS (5%), PCB and FS (5%), BBE and GBS (4%), and PCB and BBE (1%). Patients who initially had bulbar palsy developed not only PCB but FS or BBE. The population of anti-GT1a-positive patients frequently had ophthalmoplegia, ataxia, and areflexia, whereas the subpopulation who had anti-GT1a IgG without GQ1b reactivity frequently had preceding diarrhea as well as oropharyngeal, neck, and limb weakness. Patients with anti-GT1a IgG presented a variety of clinical conditions, indicative of a continuous clinical spectrum. A major part of this clinical variation was due to the coexistence of anti-GQ1b IgG. The presence of a common autoantibody (anti-GT1a IgG) and overlapping illnesses suggests that PCB is closely related not only to GBS but to FS and BBE as well.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050449     DOI: 10.1016/j.jns.2004.01.005

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Nodopathies in the Early Diagnosis of Axonal Forms of Guillain-Barré Syndrome.

Authors:  Sara Urdiales-Sánchez; José-Ramiro González-Montaña; Ricardo Diaz-Pérez; Pablo Calvo-Calleja; María-Antonia Gutiérrez-Trueba; Javier Urdiales-Urdiales
Journal:  Front Neurol       Date:  2022-05-25       Impact factor: 4.086

2.  Severe outcome of pharyngeal-cervical-brachial pure motor axonal neuropathy.

Authors:  L Bonanni; V Onofrj; V Scorrano; M Onofrj; A Thomas
Journal:  Open Neurol J       Date:  2010-01-29

3.  Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barré syndrome in Korea: a nationwide multicenter study.

Authors:  Jong Kuk Kim; Jong Seok Bae; Dae-Seong Kim; Susumu Kusunoki; Jong Eun Kim; Ji Soo Kim; Young-Eun Park; Ki-Jong Park; Hyun Seok Song; Sun Young Kim; Jeong-Geun Lim; Nam-Hee Kim; Bum Chun Suh; Tai-Seung Nam; Min Su Park; Young-Chul Choi; Eun Hee Sohn; Sang-Jun Na; So Young Huh; Ohyun Kwon; Su-Yun Lee; Sung-Hoon Lee; Sun-Young Oh; Seong-Hae Jeong; Tae-Kyeong Lee; Dong Uk Kim
Journal:  J Clin Neurol       Date:  2014-04-23       Impact factor: 3.077

Review 4.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

5.  Unilateral Abducens Nerve Palsy as an Early Feature of Multiple Mononeuropathy Associated with Anti-GQ1b Antibody.

Authors:  Ryuta Kinno; Hiroo Ichikawa; Hiroto Tanigawa; Kazuhiro Itaya; Mitsuru Kawamura
Journal:  Case Rep Neurol       Date:  2011-03-04

6.  Treatment guidelines for Guillain-Barré Syndrome.

Authors:  A K Meena; S V Khadilkar; J M K Murthy
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

7.  Recurrent Miller Fisher Syndrome.

Authors:  Say Ting Ooi; Ameilia Ahmad; Azhany Yaakub
Journal:  Cureus       Date:  2022-06-22

8.  Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis.

Authors:  Jason R Lees; Paul T Golumbek; Julia Sim; Denise Dorsey; John H Russell
Journal:  J Exp Med       Date:  2008-10-13       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.